(Health Korea News / Lee Si-woo) Bio platform company Alteogen (CEO Park Soon-jae) and Daiichi Sankyo (CEO Manabe Sunao, 眞鍋 淳) and the antibody-drug conjugate (ADC) Enhertu® (Trastuzumab Deluxe) It announced on the 8th that it signed an agreement granting an exclusive license to Tecan to develop a subcutaneous injection treatment using ALT-B4.
The total value of this contract is $300 million, with a down payment of $20 million. Additionally, if you achieve post-market sales milestones, you will receive a set royalty.
Alteogen explained, “We have been exploring the possibility of developing a subcutaneous injection type ADC by focusing on the pharmacokinetic characteristics of treatments using hyaluronidase.”
Enhertu, the product with which the contract was signed this time, is an ADC treatment jointly developed by Daiichi Sankyo and AstraZeneca. It has proven excellent treatment effects in various clinical trials and fields, including the clinical trial ‘DESTINY-Breast04’, which defined metastatic HER2 low-expression breast cancer patients for the first time and showed treatment effects. Enhertu has been designated as a Breakthrough Therapy by the FDA eight times for various cancer indications, and has become a blockbuster treatment with sales of approximately $2.78 billion in 2023.
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
